Management of Insomnia in the Elderly

Initial Assessment

• The American Geriatrics Society recommends determining if insomnia is primary or comorbid with other conditions, as older adults often have multiple contributing factors 1, 2
• Evaluate prescription and non-prescription medications that may cause or exacerbate insomnia, such as β-blockers, bronchodilators, corticosteroids, decongestants, diuretics, SSRIs, and SNRIs 3, 4
• Assess for common behaviors that impair sleep, including daytime napping, excessive time in bed, insufficient activity, evening alcohol consumption, and late heavy meals 5

Non-Pharmacological Interventions

• The American College of Physicians recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for elderly patients with chronic insomnia due to its proven efficacy, long-lasting effects, and minimal side effects compared to pharmacological options 6, 7
• CBT-I combines multiple behavioral treatments with cognitive restructuring and has demonstrated effectiveness with effects sustained for up to 2 years in older adults 6, 2
• Sleep restriction/compression therapy, which limits time in bed to match actual sleep time, can be an effective approach, with sleep compression being better tolerated by elderly patients than immediate restriction 2, 5
• Stimulus control, which strengthens the association between the bedroom and sleep, is also recommended, with key instructions including using the bedroom only for sleep and sex, leaving the bedroom if unable to fall asleep within 20 minutes, and maintaining consistent sleep and wake times 6, 8
• Sleep hygiene education, which addresses environmental factors such as comfortable bedroom temperature, noise reduction, and light control, is most effective when combined with other modalities rather than as a standalone treatment 2, 5
• Relaxation techniques, such as progressive muscle relaxation, guided imagery, and diaphragmatic breathing, can help achieve a calm state conducive to sleep onset 6, 8

Pharmacological Interventions

• The American College of Physicians recommends that pharmacotherapy should only be considered when CBT-I alone has been unsuccessful, using a shared decision-making approach that discusses benefits, harms, and costs of short-term medication use 7
• FDA-approved medications for insomnia, such as non-benzodiazepines (Z-drugs), melatonin receptor agonists, orexin receptor antagonists, and low-dose doxepin, should be started at the lowest available dose in elderly patients 6
• Medication selection should be based on symptoms, with sleep onset insomnia treated with ramelteon or short-acting Z-drugs, sleep maintenance treated with suvorexant or low-dose doxepin, and both onset and maintenance treated with eszopiclone or extended-release zolpidem 7

Common Pitfalls and Caveats

• The American Geriatrics Society recommends avoiding benzodiazepines when possible due to higher risk of adverse effects in elderly, such as falls, cognitive impairment, and dependence 6
• Sleep hygiene education alone is usually insufficient for treating chronic insomnia, and pharmacological treatments should be limited to short-term use when possible 7, 2
• Medication side effects may be more pronounced in elderly due to reduced clearance and increased sensitivity, and regular reassessment is necessary to evaluate treatment effectiveness and potential adverse effects 9, 10

Management of Insomnia in Older Adults

Initial Assessment and Treatment

• The American Geriatrics Society recommends starting treatment at the lowest available dose in elderly patients due to reduced drug clearance and increased sensitivity to peak effects 11
• The American Academy of Sleep Medicine suggests following patients every few weeks initially to assess effectiveness and side effects, and employing the lowest effective maintenance dosage and taper when conditions allow 12

Pharmacotherapy

• The American Academy of Sleep Medicine recommends starting at the lowest available dose in elderly patients due to reduced drug clearance and increased sensitivity to peak effects, and following patients every few weeks initially to assess effectiveness and side effects 12
• Sedating antidepressants (such as trazodone, amitriptyline, doxepin, mirtazapine) should only be used when comorbid depression/anxiety exists, as there is no systematic evidence for effectiveness in primary insomnia and risks outweigh benefits 11, 12
• Over-the-counter antihistamines (such as diphenhydramine) should be avoided in elderly patients, and herbal supplements (such as valerian, melatonin) are not recommended due to lack of efficacy and safety data 12

Critical Pitfalls to Avoid

• The American Academy of Sleep Medicine advises against using benzodiazepines or barbiturates as first-line agents in older adults, and against prescribing long-term pharmacotherapy without concurrent CBT-I trials whenever possible 12
• The American Geriatrics Society recommends avoiding antihistamines, antipsychotics, and anticonvulsants for primary insomnia due to unfavorable risk-benefit profiles in elderly, and monitoring regularly for adverse effects 11

Long-Term Management

• The American Academy of Sleep Medicine suggests that for patients requiring chronic hypnotic medication due to severe or refractory insomnia, administration may be nightly, intermittent (three nights per week), or as needed, with consistent follow-up and ongoing assessment 12

Management of Insomnia in Elderly Patients

Assessing Medication as a Contributing Factor

• The American Geriatrics Society suggests that SSRIs, including sertraline, are known to cause or worsen insomnia in elderly patients, making this a likely medication-induced sleep disturbance that must be addressed 13, 14
• Reviewing all medications the patient is taking is crucial, as elderly patients often take multiple drugs that disrupt sleep, including β-blockers, bronchodilators, corticosteroids, decongestants, and diuretics 13, 14

Implementing First-Line Non-Pharmacological Treatment

• The American Geriatrics Society recommends initiating cognitive behavioral therapy for insomnia (CBT-I) immediately as the primary treatment, as it provides superior long-term outcomes with effects sustained for up to 2 years in older adults without adding medication-related risks 14
• CBT-I components to implement include sleep restriction/compression therapy, stimulus control, sleep hygiene modifications, and relaxation techniques, such as having the patient keep a 2-week sleep log, limiting time in bed, and using the bedroom only for sleep and sex 15
• Sleep hygiene modifications, such as avoiding caffeine, nicotine, and alcohol in the evening, avoiding heavy exercise within 2 hours of bedtime, and ensuring the bedroom is cool, dark, and quiet, are also essential 15
• Relaxation techniques, such as progressive muscle relaxation, guided imagery, or diaphragmatic breathing, can help achieve a calm state at bedtime 15

Common Pitfalls to Avoid

• The American Geriatrics Society advises against adding a hypnotic medication before attempting CBT-I, as behavioral interventions are more effective long-term and avoid polypharmacy risks 14
• It is also important not to assume sleep hygiene education alone will suffice, as it must be combined with other CBT-I modalities for chronic insomnia 15
• Additionally, it is crucial not to overlook the sertraline as the culprit, as medication-induced insomnia is common and often missed in elderly patients on SSRIs 13, 14

Treatment for Insomnia in the Elderly

Initial Treatment Recommendations

• The American Academy of Sleep Medicine recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for elderly patients with chronic insomnia, providing superior long-term outcomes with effects sustained for up to 2 years without the risks of polypharmacy 16, 17

Non-Pharmacological Treatment

• CBT-I is effective for adults of all ages, including older adults, and should be utilized as the initial intervention when conditions permit, according to the American Academy of Sleep Medicine 16
• The American Academy of Sleep Medicine suggests that sleep hygiene education alone is insufficient for treating chronic insomnia and must be combined with other CBT-I modalities 16
• Cognitive restructuring, a component of CBT-I, can help address unrealistic sleep expectations and anxiety about sleep in elderly patients with insomnia 16

Pharmacological Treatment

• The American Academy of Sleep Medicine recommends that pharmacotherapy should only be considered when CBT-I alone has been unsuccessful, using shared decision-making that discusses benefits, harms, and costs of short-term medication use, although this specific statement is not directly cited, the general principle is supported by 16, 18, 19
• The American Geriatrics Society suggests that benzodiazepines should be avoided in elderly patients with insomnia due to higher risk of falls, cognitive impairment, dependence, and increased sensitivity in elderly 17
• The American Academy of Sleep Medicine advises against the use of over-the-counter antihistamines, barbiturates, chloral hydrate, and herbal supplements for the treatment of insomnia in elderly patients due to lack of efficacy and safety data or unfavorable risk-benefit profiles 16, 18, 19

Combination Therapy

• The American Geriatrics Society found that combining CBT-I with pharmacotherapy may provide better short-term outcomes than either modality alone, with medications providing rapid onset relief and behavioral therapy providing longer-term sustained benefit 17

Long-Term Management

• The American Academy of Sleep Medicine suggests that chronic hypnotic medication may be indicated for severe or refractory insomnia or chronic comorbid illness, but patients should receive an adequate trial of CBT-I during long-term pharmacotherapy whenever possible 18, 19
• The American Academy of Sleep Medicine recommends that medication tapering and discontinuation are facilitated by CBT-I 18, 19
• Regular reassessment is necessary to evaluate treatment effectiveness, monitor for adverse effects, and assess for new or worsening comorbid disorders, according to the American Academy of Sleep Medicine 18, 19

Sleep Disturbances in the Elderly: Non-Pharmacological and Pharmacological Interventions

Environmental Modifications for Improved Sleep

• Environmental modifications, including decreased nighttime noise and light disruption, can reduce nighttime arousals, as recommended by the American Geriatrics Society 20, 21
• Multicomponent interventions combining increased daytime physical activity, sunlight exposure, decreased time in bed during the day, bedtime routine, and decreased nighttime noise/light may decrease the duration of nighttime awakenings in nursing home residents 20, 21

Medications to Avoid in the Elderly

• The American Geriatrics Society recommends avoiding benzodiazepines, including temazepam, due to a higher risk of falls, cognitive impairment, dependence, and worsening dementia, with a randomized trial showing diphenhydramine and temazepam caused poorer neurologic function and more daytime hypersomnolence in nursing home residents 20, 22

Insomnia Treatment in Elderly Patients

Medication-Related Risks

• The use of hydroxyzine in patients with potential cognitive decline can accelerate dementia progression, due to its anticholinergic effects, as reported by the Annals of Internal Medicine 23, 24
• The American Geriatrics Society recommends avoiding antidepressants with anticholinergic burden, such as tricyclics, in older adults with depression, especially those with frailty and potential cognitive decline, according to The Lancet Healthy Longevity 25

Alternative Treatment Options

• Among SSRIs, fluoxetine is generally not recommended for older adults due to its long half-life and side effects, whereas venlafaxine, vortioxetine, and mirtazapine are safer options, as stated in The Lancet Healthy Longevity 25
• Sertraline is effective and well-tolerated in elderly patients with major depressive disorder, though it can cause insomnia as a side effect, and its use should be carefully considered in patients with sleep disturbances 23, 24

Treatment of Insomnia in Elderly Patients

Pharmacological Interventions

• Low-dose doxepin (3-6mg) is the most appropriate medication for sleep maintenance insomnia in older adults, with demonstrated improvement in total sleep time, wake after sleep onset, and sleep quality, according to the American Academy of Sleep Medicine 26
• Long-term use of benzodiazepines, even at low intermittent doses, is associated with an increased risk of dementia, particularly with higher doses and longer half-lives, as reported by the Annals of Internal Medicine 27

Management of Insomnia in Elderly Patients

First-Line Treatment

• The American Academy of Sleep Medicine emphasizes that short-term hypnotic treatment should be supplemented with behavioral and cognitive therapies when possible 28

Pharmacotherapy

• The American Academy of Sleep Medicine recommends that combined therapy decisions should be directed by symptom pattern, treatment goals, past treatment responses, patient preference, comorbid conditions, contraindications, and concurrent medication interactions 28
• Eszopiclone dosing for elderly patients should start at 1-2 mg, due to reduced drug clearance and increased sensitivity to peak effects 28

Medication Selection

• Barbiturates and chloral hydrate are not recommended for treatment of insomnia 28
• Herbal supplements, such as valerian and melatonin, are not recommended due to lack of efficacy and safety data 28

Monitoring and Follow-Up

• The American Academy of Sleep Medicine recommends employing the lowest effective maintenance dosage and tapering medication when conditions allow 28
• Medication tapering and discontinuation are facilitated by CBT-I, making concurrent behavioral therapy essential even during pharmacotherapy 28
• For patients requiring chronic hypnotic medication, administration may be nightly, intermittent, or as needed, with consistent follow-up and ongoing assessment 28
• The American Academy of Sleep Medicine recommends that patients should receive an adequate trial of cognitive behavioral treatment during long-term pharmacotherapy 28

Pharmacological Alternatives for Chronic Insomnia in Elderly Patients

Recommended Pharmacological Alternatives

• The American Academy of Sleep Medicine suggests that melatonin 2mg has very low quality evidence for efficacy in elderly insomnia, with meta-analysis showing no clinically significant improvement in sleep quality (SMD +0.21, CI: -0.36 to +0.77) 29

Melatonin Considerations

• The American Academy of Sleep Medicine indicates that melatonin may be most effective in elderly patients with documented low melatonin levels or those chronically using benzodiazepines, with optimal timing 1-2 hours before bedtime (around 6 PM) to regulate circadian rhythms 29

Evidence‑Based Management of Insomnia in Older Adults with Hypertension

Medication Review and Potential Contributors

• β‑blockers (e.g., propranolol, metoprolol, atenolol) frequently cause insomnia and nightmares in older patients. 30
• Evening administration of diuretics can disrupt sleep by producing nocturia. 30
• Bronchodilators, systemic corticosteroids, and decongestants may impair sleep when used for comorbid conditions. 30
• Switching from β‑blockers to alternative antihypertensive agents such as thiazide diuretics, calcium‑channel blockers, ACE inhibitors, or ARBs can improve sleep quality. 30

First‑Line Behavioral Therapy (Cognitive Behavioral Therapy for Insomnia – CBT‑I)

• CBT‑I is the gold‑standard initial treatment for older adults, with benefits sustained up to two years and no medication‑related risks. (American Academy of Sleep Medicine) 31
• A 1–2‑week sleep log is used to calculate mean total sleep time (TST) for individualized time‑in‑bed (TIB) prescription. (American Academy of Sleep Medicine) 31
• Prescribed TIB should match the calculated TST while maintaining sleep efficiency ≥85 %; TIB must never be set below 5 hours. (American Academy of Sleep Medicine) 31
• Weekly TIB adjustments are recommended: increase by 15–20 minutes if sleep efficiency >85–90 %, decrease by 15–20 minutes if <80 %. (American Academy of Sleep Medicine) 31
• Stimulus‑control instructions—use the bedroom only for sleep/sex, leave the bedroom if unable to fall asleep within ~20 minutes, return only when sleepy, keep consistent sleep‑wake times, and avoid daytime napping—are core components of CBT‑I. (American Academy of Sleep Medicine) 31
• Sleep‑hygiene modifications (cool, dark, quiet bedroom; avoid evening caffeine, nicotine, alcohol; avoid vigorous exercise within 2 hours of bedtime; limit fluids before sleep) must be combined with other CBT‑I modalities for effectiveness. (American Academy of Sleep Medicine) 31

Pharmacologic Options When CBT‑I Fails (Second‑Line Treatment)

• Short‑acting Z‑drugs (e.g., zolpidem 5 mg) are an alternative for sleep‑onset insomnia in elderly patients after CBT‑I failure. (American Academy of Sleep Medicine) 31
• Eszopiclone 1–2 mg (starting at 1 mg) is appropriate for combined sleep‑onset and maintenance insomnia in older adults, without a short‑term usage restriction. (American Academy of Sleep Medicine) 31
• Extended‑release zolpidem 6.25 mg is another option for combined insomnia symptoms in the elderly. (American Academy of Sleep Medicine) 31

Medications to Avoid in Older Adults

• Benzodiazepines (e.g., temazepam, lorazepam, clonazepam) carry higher risks of falls, cognitive impairment, and dependence and are contraindicated as first‑line agents. (American Geriatrics Society) 32
• Over‑the‑counter antihistamines (e.g., diphenhydramine, hydroxyzine) have anticholinergic effects that can accelerate cognitive decline and cause daytime hypersomnolence; they should be avoided. (American Geriatrics Society) 32
• Sedating antidepressants (e.g., trazodone, amitriptyline, mirtazapine) lack systematic evidence for primary insomnia treatment and add anticholinergic burden; use only when comorbid depression or anxiety is present. (American Academy of Sleep Medicine) 31
• Barbiturates, chloral hydrate, and herbal sedatives such as valerian are not recommended due to insufficient efficacy and safety data. (American Academy of Sleep Medicine) 31

Implementation Details of CBT‑I (Practical Guidance)

• Do not prescribe hypnotic medication before attempting CBT‑I, as behavioral interventions provide superior long‑term outcomes and reduce polypharmacy risk. (American Academy of Sleep Medicine) 31
• Sleep‑hygiene education alone is insufficient for chronic insomnia; it must be combined with other CBT‑I components. (American Academy of Sleep Medicine) 31
• Medication‑induced insomnia is frequently overlooked; β‑blockers and diuretics are common culprits in older patients. (Trends in Cardiovascular Medicine) 30

Cannabidiol Is Not Recommended for Insomnia in Older Adults

Guideline Stance on Cannabidiol

• The American College of Physicians (2016) and the American Geriatrics Society (2009) do not list cannabidiol (CBD) as a therapeutic option for insomnia in older adults; it is absent from their evidence‑based recommendations. 33
• Evidence‑based insomnia guidelines for the elderly contraindicate herbal supplements, including CBD, because of insufficient data on efficacy and safety. 34
• No major medical society guideline (e.g., ACP, AGS) recognizes CBD as an approved or recommended treatment for sleep disorders in any age group. 33

First‑Line Non‑Pharmacologic Therapy

• The American College of Physicians recommends cognitive‑behavioral therapy for insomnia (CBT‑I) as the first‑line treatment for chronic insomnia in older adults, with benefits sustained for up to 2 years and no medication‑related risks. 35
• CBT‑I has moderate‑quality evidence for improving remission rates, treatment response, sleep‑onset latency, wake‑after‑sleep‑onset, sleep efficiency, and overall sleep quality in the elderly population. 35

Pharmacologic Options (Second‑Line, After CBT‑I Failure)

• Eszopiclone (1–2 mg), zolpidem (5 mg immediate‑release or 6.25 mg extended‑release), and suvorexant demonstrate low‑to‑moderate quality evidence for treating sleep‑maintenance insomnia in older adults. 35

Medications to Avoid or Use With Caution

• Benzodiazepines are associated with a higher risk of falls, cognitive impairment, dependence, and an increased incidence of dementia in older adults; they should be avoided. 33
• Sedating antidepressants such as trazodone and amitriptyline lack systematic evidence for primary insomnia and present risks that outweigh potential benefits in the elderly. 34

Comprehensive Medication Review & Sleep Hygiene

• A systematic review of medications that can cause or worsen insomnia in older adults recommends evaluating β‑blockers, bronchodilators, corticosteroids, decongestants, diuretics, and selective serotonin reuptake inhibitors (SSRIs). 34
• Sleep‑hygiene education alone is insufficient for chronic insomnia in older adults; it should be combined with other CBT‑I components (e.g., stimulus control, sleep restriction, relaxation techniques). 35

Evidence‑Based Management of Sleep‑Maintenance Insomnia in Older Adults

Cognitive‑Behavioral Therapy for Insomnia (CBT‑I)

• In elderly patients with sleep‑maintenance insomnia, delivering CBT‑I concurrently with any pharmacologic agent (including sleep restriction, stimulus control, sleep‑hygiene education, and relaxation techniques) produces superior long‑term sleep consolidation and enables later tapering of hypnotic medication, as endorsed by the American Academy of Sleep Medicine. 36

Screening for Co‑existing Sleep Disorders

• For older adults being treated for insomnia, clinicians should systematically screen for obstructive sleep apnea, restless‑legs syndrome, and REM‑behavior disorder because untreated comorbid sleep disorders can diminish treatment efficacy; this recommendation is supported by the American Geriatrics Society. 37

Alternative Non‑Controlled Pharmacologic Options

• If low‑dose doxepin is ineffective or not tolerated, ramelteon 8 mg taken at bedtime—a melatonin‑receptor agonist that does not require DEA licensure—may be used to aid circadian‑rhythm regulation, although the evidence for its ability to maintain sleep is weaker than that for doxepin. 36

First‑Line Management of Chronic Insomnia in Older Adults

First‑Line Behavioral Therapy

• Cognitive behavioral therapy for insomnia (CBT‑I) is the recommended first‑line treatment for chronic insomnia in elderly patients and should be started before any hypnotic medication. 38
• CBT‑I can be delivered within primary‑care settings, making it readily accessible for routine practice in older adults. 38

Evidence of Long‑Term Benefit and Safety

• In older adults, CBT‑I provides superior long‑term outcomes that can be sustained for up to two years and avoids medication‑related risks such as falls, cognitive impairment, fractures, and dementia. 38

Guideline Recommendations (American College of Physicians, FDA)

• The American College of Physicians states that CBT‑I offers greater overall value than pharmacologic therapy because it is non‑invasive and carries fewer serious harms, including dementia, serious injury, and fractures. 38
• The American College of Physicians advises that hypnotic pharmacotherapy be considered only after CBT‑I has failed, using shared decision‑making that discusses short‑term benefits, harms, and costs. 38
• The FDA recommends initiating insomnia medications at lower doses in older adults due to reduced drug clearance and increased sensitivity to peak effects. 38
• FDA‑approved hypnotics are indicated for short‑term use (typically 4–5 weeks); prolonged continuous use is discouraged. 38

Medication Safety and Contraindications

• Benzodiazepines (e.g., temazepam, lorazepam, clonazepam, triazolam, flurazepam, quazepam) are contraindicated as first‑line agents in older adults because they raise the risk of falls, cognitive impairment, dependence, and dementia. 38
• Observational studies have linked hypnotic drugs, albeit infrequently, to serious adverse outcomes—including dementia, severe injury, and fractures—supporting limited use in the elderly. 38
• Bronchodilators, corticosteroids, and decongestants may impair sleep when used for comorbid conditions in older patients and should be reviewed during insomnia assessment. 38

Adjunctive Considerations

• Sleep‑hygiene education alone is insufficient for chronic insomnia in older adults; it must be combined with core CBT‑I components such as sleep restriction, stimulus control, and relaxation techniques. 38